The annual awards are one of the university’s highest recognitions for interdisciplinary research achievement and honor the faculty, staff and external partners whose work exemplifies the U of A’s commitment to inquiry, innovation and societal impact. The recognition program, which is hosted by the Office of Research and Partnerships, highlights those advancing transformative research and creative activity across disciplines, sectors and communities.Continue reading
Category Archives: AZBio News
Critical Path Institute Awards $456,000 Grant to Advance Next-Generation Therapy for Rare Glycolipid Storage Disorders
TUCSON, Ariz., April 28, 2026 — Critical Path Institute® (C-Path) today announced a $456,000 grant to James Shayman, M.D., at the University of Michigan, to support development of a brain-penetrant therapy for glycosphingolipid storage disorders. Continue reading
C-Path Podcast Highlights Bold Ideas in Drug Development
The Critical Path Institute Podcast started connecting the dots for health innovators around the world one year ago. What started as a bold idea to bring the world of drug development, regulatory science, and clinical research to life through conversation has grown into a rich library of episodes covering everything from clinical outcome assessments and pediatric drug development to rare disease research and the power of data collaboration. Continue reading
AZBio Member Spotlight – Breakthru Medicine
Breakthru Medicine is advancing a portfolio of innovative cancer therapeutics designed to address critical unmet clinical needs.Continue reading
Incubate and Manatt Release New Report: Regulatory Instability at FDA Is Reshaping Biotech Investment
WASHINGTON (April 21) — Today, Incubate, in partnership with Manatt Health, released new insights from interviews with leading biopharmaceutical investors showing that instability at the Food and Drug Administration (FDA) is increasingly shaping investment decisions. In short, investors aren’t just evaluating science — they’re reassessing whether the U.S. regulatory environment is predictable enough to support it.Continue reading
Nectero Therapeutics Reports Two-Year Safety and Efficacy Data from First-in-Human Trial for Treatment of Small- to Medium-Sized Abdominal Aortic Aneurysms
London, England – April 23, 2026 – Nectero Therapeutics, a clinical-stage biotechnology company developing therapies for aneurysmal disease, released two-year outcomes data today from the company’s first-in-human (FIH) trial of their investigational Nectero EAST® System. The results were presented at Charing Cross 2026 by Dr. Andrew Holden during a session on Abdominal Aortic Aneurysm (AAA) disease management.Continue reading
CMS and FDA Announce RAPID Coverage Pathway to Accelerate Patient Access to Life-Changing Medical Devices
New pathway cuts red tape and brings predictability to Medicare coverage for Breakthrough DevicesContinue reading
ASU’s Panchanathan to lead Phoenix Quantum Strategy
Mayor announces initiative aimed at positioning city — and its economy — at forefront of ‘next era of breakthrough technology’Continue reading
Jake Birecki Makes Space for Passion, Purpose and Play
AZBio Members are driven by their commitment to improve the lives of patients and their families. At BioMarin, part of this commitment includes sharing the stories of the people they work to serve. In the first edition of their “Making Space” series, BioMarin profiled Arizona-native Jake Birecki.Continue reading
AIRNA Joins C-Path’s Alpha-1 Antitrypsin Deficiency Consortium to Advance Innovative AATD Treatments
AIRNA, a clinical-stage company developing RNA-editing medicines with an initial focus on AATD, joins C-Path’s antitrypsin consortium upon initiation of its RepAIR1 global clinical study.Continue reading